Trimotil100 mg

Trimotil is used for the symptomatic management of functional gastrointestinal disorders. The strength of evidence and typical role in therapy vary by indication, as summarized below.

Guideline/widely accepted uses

• Irritable bowel syndrome (IBS): Trimotil is used to relieve abdominal pain, cramping, bloating, and altered bowel habits (diarrhea-predominant, constipation-predominant, or mixed) associated with IBS.
• Functional dyspepsia and other functional GI motility disorders: Trimotil is used to relieve upper abdominal discomfort, bloating, and early satiety linked to disordered GI motility.

Adjunct / supportive use

• Trimotil is used as an adjunct, together with dietary and lifestyle measures, for general GI spasm and dysmotility symptoms, and in some countries as part of post-operative care to help restore normal bowel motility after abdominal surgery.

Evidence note

Trimotil is a long-marketed agent in several countries; however, robust, modern high-quality randomized trial evidence is limited in some regulatory jurisdictions, and it is not approved by the US FDA. Prescribing should follow local regulatory labeling and clinical judgment, and Trimotil should not be used in place of proper evaluation of alarm symptoms (see Precautions and Warnings).

Each tablet/capsule contains Trimebutine Maleate as the active pharmaceutical ingredient, commonly available in 100 mg and 200 mg oral dosage strengths, along with standard pharmaceutically acceptable excipients. Oral suspension formulations of Trimebutine Maleate are also available in some markets. Exact strength and excipients vary by manufacturer and brand; refer to the specific product packaging/leaflet.

Trimotil is a gastrointestinal antispasmodic and motility-modulating (normalizing) agent. It acts on peripheral opioid receptors in the smooth muscle and enteric nervous system of the gut, giving it a dual "modulator" effect: it can reduce excessive, spasmodic gut contractions while also stimulating motility when the gut is hypomotile. Trimotil is used mainly for symptomatic relief in irritable bowel syndrome and other functional gastrointestinal motility disorders, and is generally well tolerated.

Gastrointestinal antispasmodic and motility-modulating agent (Trimotil is a peripherally-acting opioid receptor agonist affecting GI smooth muscle).

Trimebutine Maleate acts as an agonist at peripheral mu, kappa, and delta opioid receptors located on the smooth muscle and enteric (myenteric and submucosal plexus) neurons of the gastrointestinal tract. Through this combined musculotropic and neurotropic action, Trimebutine Maleate normalizes gastrointestinal motility: it has an inhibitory (spasmolytic) effect on hypercontractile or spastic gut segments and a stimulant (prokinetic) effect on hypomotile segments, without disrupting normal peristalsis. Trimebutine Maleate is also reported to reduce visceral hypersensitivity, which contributes to relief of abdominal pain in functional GI disorders.

Pharmacokinetically, Trimebutine Maleate is rapidly absorbed after oral administration, undergoes hepatic metabolism, and is eliminated mainly via the kidneys, with a short elimination half-life supporting a multiple-times-daily dosing schedule.

Trimotil tablets/capsules should be taken orally, generally before meals, swallowed with a glass of water. Oral suspension forms of Trimotil, where available, should be measured using the calibrated device provided with the product. Trimotil should be taken at evenly spaced intervals as directed by the physician, and the course should be completed as advised rather than stopped as soon as symptoms improve, unless the physician says otherwise.

Well-characterized, clinically significant drug interactions with Trimotil are limited in the available literature. General precautions include:

• CNS depressants / other opioid-receptor-acting agents: Because Trimotil acts on opioid receptors peripherally, theoretical additive effects (e.g., increased sedation) with centrally-acting opioids or sedatives cannot be excluded; use with caution if co-administered.
• Other GI motility-affecting drugs: Concurrent use of Trimotil with other agents that significantly alter GI motility should be monitored clinically, as effects may be additive or opposing.

Patients should inform their physician or pharmacist of all other medicines, supplements, and herbal products being taken before starting Trimotil.

Trimotil is generally well tolerated. Reported adverse effects include:

• Dry mouth, drowsiness, or dizziness
• Gastrointestinal disturbances such as constipation or diarrhea
• Skin reactions: rash, pruritus, or urticaria
• Rare reports of transient elevation of liver enzymes
• Rare hypersensitivity reactions

Patients should seek medical advice if any side effect from Trimotil is severe, persistent, or concerning.

Data on the use of Trimotil in human pregnancy are limited. Trimotil should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use.

It is not well established whether Trimotil passes into human breast milk. As a precaution, Trimotil should be used during breastfeeding only after consulting a physician, weighing benefits against potential risk to the infant.

Trimotil should be used with the following precautions:

• Evidence base: high-quality modern randomized trial data supporting Trimotil are limited in some regulatory settings, and Trimotil is not approved by the US FDA; use should follow local product labeling and physician judgment.
• Alarm symptoms: Trimotil is intended for symptomatic relief of functional GI disorders. It is not a substitute for proper diagnostic evaluation. Patients with alarm features such as unintentional weight loss, GI bleeding, anemia, persistent vomiting, dysphagia, a palpable abdominal mass, or onset of symptoms after age 50 should undergo further medical workup rather than relying on symptomatic treatment with Trimotil alone.
• Hepatic/renal impairment: use Trimotil cautiously and under physician supervision, as formal dose-adjustment data are limited.
• Driving/operating machinery: because Trimotil can occasionally cause drowsiness or dizziness, patients should assess their individual response before driving or operating machinery.

Limited data exist on Trimotil overdose in humans; exaggerated pharmacologic effects such as marked drowsiness, dizziness, or gastrointestinal upset may be expected. In case of suspected overdose of Trimotil, seek immediate medical attention or contact a poison control center. Treatment is supportive and symptomatic, guided by a physician; there is no specific antidote.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric patients: Safety and efficacy of Trimotil are not established for all pediatric age groups; where a pediatric formulation is locally licensed, use only under direct physician supervision with weight/age-based dosing (see Pediatric Uses).

Elderly patients: No major dose adjustment is generally required for Trimotil in the elderly, but use with routine caution given the higher likelihood of concurrent illness and polypharmacy in this group.

Hepatic/renal impairment: Use Trimotil cautiously with physician oversight; formal dose-adjustment guidelines are not well established (see Precautions and Warnings).

Pregnancy/lactation: See Pregnancy and Lactation section for full guidance on Trimotil.

Treatment with Trimotil for functional GI disorders such as IBS or functional dyspepsia is typically given as a trial course of several weeks (commonly around 4 to 8 weeks), with the physician reassessing symptom response before continuing, adjusting, or stopping Trimotil. Long-term use of Trimotil should be periodically reviewed by the prescribing physician.

Gastrointestinal antispasmodics; GI motility-modulating agents (prokinetic/spasmolytic); peripherally-acting opioid receptor agonists.

Trimebutine Maleate acts as an agonist at peripheral mu, kappa, and delta opioid receptors on GI smooth muscle and the enteric nervous system. This dual musculotropic and neurotropic action allows Trimebutine Maleate to normalize gastrointestinal motility - inhibiting excessive/spastic contractions while stimulating motility where it is reduced - and to lower visceral hypersensitivity, without acting on the central nervous system in a clinically significant way at usual doses.

Use of Trimotil in children should be conservative and physician-directed. Safety and efficacy of Trimotil have not been firmly established across all pediatric age groups, and in many regulatory jurisdictions pediatric labeling is limited or absent. Where a locally licensed pediatric oral suspension of Trimotil exists, dosing is weight/age-based per that product's specific labeling. Trimotil should not be given to infants or young children except on the explicit advice of a pediatrician, who will weigh the potential benefit against the limited pediatric safety data.